Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.

The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.

Inclusion Criteria:

• female or male of 50 to 85 years old with a care giver
• Mini Mental Status (MMS) test between 16 to 26 inclusive
• Clinical Dementia Rating (CDR) test inferior or equal to 1
• National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease
• Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementia

Exclusion Criteria:

• patient already treated by medicines which could interfere with the study
• low level of vitamin B12 and folate which are considered as clinically relevant
• clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness….)